Alterity Therapeutics Limited

NasdaqCM ATHE

Alterity Therapeutics Limited Price to Sales Ratio (P/S) on December 05, 2024

Alterity Therapeutics Limited Price to Sales Ratio (P/S) is NA on December 05, 2024, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Alterity Therapeutics Limited 52-week high Price to Sales Ratio (P/S) is 6.60 on November 26, 2024, which is NA below the current Price to Sales Ratio (P/S).
Alterity Therapeutics Limited 52-week low Price to Sales Ratio (P/S) is 4.98 on November 20, 2024, which is NA below the current Price to Sales Ratio (P/S).
Alterity Therapeutics Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 5.44.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: ATHE

Alterity Therapeutics Limited

CEO	Dr. David A. Stamler M.D.
IPO Date	Sept. 29, 2003
Location	Australia
Headquarters	460 Bourke Street
Employees	10
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Key trends

Past 5 years